Kyverna Therapeutics reported a net loss of $119.99 million for the nine months ended September 30, 2026, compared to $123.50 million in the prior year period. The company's cash and marketable securities position decreased to $170.57 million as of September 30, 2026, down from $279.25 million at the end of 2025, primarily due to ongoing research and development expenses.
Kyverna Therapeutics reported Q3 2026 financial results and announced the completion of its rolling BLA submission to the FDA for miv-cel in Stiff Person Syndrome (SPS). The company ended the quarter with $312.4 million in cash and equivalents, which it expects will fund operations into 2028 as it prepares for a potential commercial launch in 2027.
Term
Q3 2026
“Kyverna is very proud to submit the first BLA for a CAR T-cell therapy in autoimmune disease, paving the way for a potential new standard of care with a single dose, designed to reset the immune system and free patients from lifelong disease and chronic immunotherapies.”
Kyverna Therapeutics announced positive one-year topline data from its KYSA-8 registrational trial for miv-cel in stiff person syndrome (SPS) and longer-term follow-up data from its KYSA-6 trial in generalized myasthenia gravis (gMG). The results demonstrated durable clinical responses and a favorable safety profile, supporting the company's plan to complete a rolling BLA submission for SPS in Q4 2026.